ArticleBMC medical genomics2015
Integrative analysis of survival-associated gene sets in breast cancer.
Article in BMC medical genomics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 19 citations in OpenAlex.
- Integrated Expression Analysis May Support Serine/Threonine Kinases as Common Hub Genes in Breast Cancer.Iranian journal of medical sciences · 2025Article
- Detecting Cancer Survival Related Gene Markers Based on Rectified Factor Network.Frontiers in bioengineering and biotechnology · 2020Article
- Cytokine sensitivity screening highlights BMP4 pathway signaling as a therapeutic opportunity in ERFASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2019Article
- Therapeutically targeting tumor microenvironment-mediated drug resistance in estrogen receptor-positive breast cancer.The Journal of experimental medicine · 2018Article
- Comparison of multiple transcriptomes exposes unified and divergent features of quiescent and activated skeletal muscle stem cells.Skeletal muscle · 2017Article
- A novel pathway-based distance score enhances assessment of disease heterogeneity in gene expression.BMC bioinformatics · 2017Article
- Contextual Refinement of Regulatory Targets Reveals Effects on Breast Cancer Prognosis of the Regulome.PLoS computational biology · 2017Article
- Adaptive immunity programmes in breast cancer.Immunology · 2017Review
- A network medicine approach to build a comprehensive atlas for the prognosis of human cancer.Briefings in bioinformatics · 2016Article
- Integrative Genomic Analyses Yield Cell-Cycle Regulatory Programs with Prognostic Value.Molecular cancer research : MCR · 2016Article
- Systematic analysis of hematopoietic gene expression profiles for prognostic prediction in acute myeloid leukemia.Scientific reports · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
backgroundPatient gene expression information has recently become a clinical feature used to evaluate breast cancer prognosis. The emergence of prognostic gene sets that take advantage of these data has led to a rich library of information that can be used to characterize the molecular nature of a patient's cancer. Identifying robust gene sets that are consistently predictive of a patient's clinical outcome has become one of the main challenges in the field.
methodsWe inputted our previously established BASE algorithm with patient gene expression data and gene sets from MSigDB to develop the gene set activity score (GSAS), a metric that quantitatively assesses a gene set's activity level in a given patient. We utilized this metric, along with patient time-to-event data, to perform survival analyses to identify the gene sets that were significantly correlated with patient survival. We then performed cross-dataset analyses to identify robust prognostic gene sets and to classify patients by metastasis status. Additionally, we created a gene set network based on component gene overlap to explore the relationship between gene sets derived from MSigDB. We developed a novel gene set based on this network's topology and applied the GSAS metric to characterize its role in patient survival.
resultsUsing the GSAS metric, we identified 120 gene sets that were significantly associated with patient survival in all datasets tested. The gene overlap network analysis yielded a novel gene set enriched in genes shared by the robustly predictive gene sets. This gene set was highly correlated to patient survival when used alone. Most interestingly, removal of the genes in this gene set from the gene pool on MSigDB resulted in a large reduction in the number of predictive gene sets, suggesting a prominent role for these genes in breast cancer progression.
conclusionsThe GSAS metric provided a useful medium by which we systematically investigated how gene sets from MSigDB relate to breast cancer patient survival. We used this metric to identify predictive gene sets and to construct a novel gene set containing genes heavily involved in cancer progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.